Researcher Next
Create account
← Back to directory

Dariusz M. Kowalski

Researcher Next ID · RN-024977

Researcher · Medicine

Inserm

Paris, Poland

Sign in to saveSign in to claim
Not currently recruitingFunding unknown
Works count
332
Citation count
28,842
H-index
44
i10-index
101

Research interests

Medicine
Lung Cancer Treatments and Mutations
Cancer Immunotherapy and Biomarkers
Lung Cancer Research Studies
Lung Cancer Diagnosis and Treatment
Neuroendocrine Tumor Research Advances

Publications

  • Overall Survival with Osimertinib in Resected EGFR -Mutated NSCLC

    New England Journal of Medicine · 2023 · 10.1056/nejmoa2304594

  • Pembrolizumab Plus Chemotherapy in Squamous Non–Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study

    Journal of Clinical Oncology · 2023 · https://doi.org/10.1200/jco.22.01990

  • Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor–Mutated, MET -Amplified Non–Small Cell Lung Cancer: TATTON

    Cancer Discovery · 2022 · https://doi.org/10.1158/2159-8290.cd-22-0586

  • First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial

    The Lancet · 2021 · https://doi.org/10.1016/s0140-6736(20)32714-8

  • Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study

    The Lancet Oncology · 2020 · https://doi.org/10.1016/s1470-2045(19)30785-5

  • Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial

    The Lancet Oncology · 2020 · https://doi.org/10.1016/s1470-2045(20)30539-8

  • Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations

    New England Journal of Medicine · 2020 · https://doi.org/10.1056/nejmoa2004407

  • Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

    The Lancet · 2019 · https://doi.org/10.1016/s0140-6736(18)32409-7

  • Phase 3 study of carboplatin-paclitaxel/nab-paclitaxel (Chemo) with or without pembrolizumab (Pembro) for patients (Pts) with metastatic squamous (Sq) non-small cell lung cancer (NSCLC).

    Journal of Clinical Oncology · 2018 · https://doi.org/10.1200/jco.2018.36.15_suppl.105

  • Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study

    The Lancet Oncology · 2018 · https://doi.org/10.1016/s1470-2045(18)30144-x

  • Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer

    New England Journal of Medicine · 2018 · 10.1056/nejmoa1810865

  • Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

    The Lancet · 2016 · https://doi.org/10.1016/s0140-6736(16)32517-x

Current projects

    No projects listed.